Search PubMed⌕ Search

Biomedical subjects

G Ziemer

Publications and source records attributed to G Ziemer.

At least 55 records · Page 3Linked to original sources
PubMed2000

Quality assessment of heparin coatings by their binding capacities of coagulation and complement enzymes.

In vitro testing of blood contacting materials before clinical application is generally advisable. Four heparin coatings from different manufacturers were tested for adsorbed proteins and soluble activation markers. The surface with the highest antithrombin, thrombin, high-molecular-weight-kininogen (HMWK) and the lowest fibrinogen binding capacity (Carmeda, Medtronic) showed significantly lower levels of granulocytes and platelet activation (beta-TG, PMN-elastase release). No statistically significant differences in soluble markers of the coagulation system could be detected (F1 + 2, TAT). Interestingly, complement activation (TCC) was significantly reduced within the group of the lowest adsorption of the complement factor C3. Our data demonstrate that there is a relation between the binding affinity of proteins (C1-inhibitor, C3-complement) and the consecutive changes in complement activation (TCC). Therefore, measuring adsorbed proteins on artificial surfaces is a suitable, sensitive and very reproducible method for assessing the thrombogenicity of biomaterials.

Adsorption↗
PubMed2000

[Comparative studies of the adsorption behavior of plasma proteins to heparin-coated surfaces].

Over the past 10 years, investigations have shown that heparin coating optimizes haemocompatibility in extracorporeal circulation systems. To date, however, the mechanisms involved have not been identified. 20 ml of fresh human blood were circulated in an in vitro closed-loop model with and without heparin coating. Using a newly developed ELISA, a quantitative analysis of the adsorbed plasma proteins was done. In addition, changes in coagulation, complement and blood cell releasing factors were measured by ELISA methods: prothrombin fragment 1 + 2 (F1 + 2), thrombin-antithrombin-III complex (TAT), PMN-elastase, beta-thromboglobulin (beta-TG) and terminal complement-complex (TCC). In uncoated tubing, high concentrations of fibrinogen, fibronectin, prothrombin, vitronectin, alpha 2-macroglobulin, von Willebrand factor and complement factor C3 were found. Large amounts of antithrombin-III, HMWK and C1-esterase inhibitor were found on the heparinized surfaces. In addition, the concentrations of the soluble plasma protein markers F1 + 2, FPA, PMN-elastase, TCC and beta-TG were significantly lower (p < 0.05) in the presence of heparin coating. The haemocompatibility of "foreign" surfaces depends largely on the extent to which the processes of activation and inhibition of humoral and cellular mediators permanently occurring at the natural endothelium can be simulated. Owing to the low adsorption of procoagulatory and proinflammatory enzymes, heparin-coated surfaces demonstrate significantly improved haemocompatibility.

Adsorption↗
PubMed2000

Repeated delayed sternal closure with stenting for right and left heart failure.

Delayed sternal closure is an established method to overcome circulatory instability, especially in pediatric cardiac surgery. We describe the management of complications in a seven-year-old boy in whom staged chest closure augmented by sternal stenting was used twice within three weeks, once for right heart and once for left heart failure.

Cardiac Output, Low↗
PubMed1999

Increased coagulation and bradykinin-release in shed pleural blood during cardiac surgery.

Retransfusion of shed pleural blood is generally believed to contribute to a decrease of intraoperative blood requirements, however, hemodynamic or hemostatic side effects are nevertheless still controversial. Some 13 patients (age: 58 +/- 11) undergoing CPB surgery including the use of the internal mammaria artery (IMA) were investigated. For IMA preparation, pleura of the left hemithorax was opened, allowing blood to accumulate within the pleural cavity. Some 472 +/- 258 ml blood volumes were retransfused after 79 +/- 11 min clamp time. After 50 +/- 15 s, mean arterial blood pressure (AP) dropped from 68 +/- 15 to 36 +/- 8 mm Hg, and the calculated systemic vascular resistance (SVR) decreased from 1124 +/- 263 to 596 +/- 153 dyn s(-1) cm5 (p < 0.01). Bradykinin levels in the retransfused shed blood showed significantly higher values (205 +/- 88 fmol/ml) compared to the systemic blood (24 +/- 19 fmol/ml). Thrombin-antithrombin-III complexes were strongly elevated in the shed pleural blood, and after retransfusion the systemic blood values increased significantly. After retransfusion of shed pleural blood during CPB an acute drop in AP and SVR occurred, probably caused by high bradykinin concentrations. We therefore recommend that the accumulation of shed blood is avoided by continuous retransfusion as is now the standard procedure in our University hospital.

Blood Coagulation Disorders↗
PubMed1999

Resection of a large right atrial hemangioma in a neonate after prenatal diagnosis.

Cardiac hemangiomas are extremely rare benign tumors. We describe the case of a right atrial hemangioma in a neonate diagnosed prenatally and successfully operated 10 days after spontaneous delivery. This unusual case illustrates the importance of prenatal diagnosis and delivery of the baby next to a pediatric center with a department of appropriately specialized cardiovascular surgery.

Female↗
PubMed1999

Preparatory surgical stent placement facilitating extracardiac vascular connections.

Native pericardium can be valuable material for the construction of extracardiac vascular connections. To avoid its scarring by adhesions and to preform future vascular connections, ringed polytetrafluoroethylene prostheses were implanted into the pericardial sac during staged operations for univentricular heart disease. At reoperation, extracardiac connections were found to be greatly facilitated by this approach.

Anastomosis, Surgical↗
PubMed1999

Aprotinin in fibrin tissue adhesives induces specific antibody response and increases antibody response of high-dose intravenous application.

BACKGROUND: In cardiac operations, aprotinin therapy is used either locally as a component of commercially available fibrin tissue adhesives, intravenously, or combined. Our aim was to examine the formation of aprotinin-specific antibodies with regard to the application mode. METHODS: Sera of 150 patients who had undergone cardiac operations and were receiving aprotinin therapy for the first time were sampled before the operation and at medians of 3.5 and 13.3 months after the operation. Aprotinin-specific IgG including all subgroups and aprotinin-specific IgE were analyzed. Aprotinin was given locally (as contained in fibrin sealant; n = 45; median dose, 6000 KIU), intravenously (n = 46; 2.000 x 10(6) KIU), and combined (n = 59; 2.012 x 10(6) KIU). RESULTS: At 3.5 months, the prevalence of aprotinin-specific IgG antibodies was 33% (15/45 patients) after local, 28% (13/46 patients) after intravenous, and 69% (41/59 patients) after combined exposure (P =.0001). At 13.3 months, the prevalence of aprotinin-specific IgG antibodies was 10% (4/41 patients) after local, 31% (13/42 patients) after intravenous, and 49% (28/57 patients) after combined exposure. Total aprotinin dose was similar in patients who were antibody positive and negative. Before the operation, no aprotinin-specific antibodies were detected. Aprotinin-specific IgE were not found after the operation. CONCLUSION: Local aprotinin contact induces a specific immune response and reinforces that of intravenous exposure. The antibody spectrum is identical to the immune response induced by intravenous exposure. Any exposure should be documented. For use in cardiac operations as a hemostyptic, the necessity itself and alternatives for aprotinin as a stabilizing agent merit consideration.

Antibody Formation↗
PubMed1999

Increased adsorption of high molecular weight kininogen to heparin-coated artificial surfaces and correlation to hemocompatibility.

During the past 10 years investigations have demonstrated that heparin-coated devices used for extracorporeal circuits show an improved hemocompatibility. We investigated the pathway of adsorption of plasma proteins at heparin-coated artificial surfaces and the further activation of the humoral and cellular defense mechanisms of the blood. Twenty milliliters of fresh human blood (1 IU heparin/ml) filled a 50 cm long tubes (with and without covalent heparin-coating), prepared as an in vitro "Closed-Loop" model and recirculated at a temperature of 37 degrees C. After 5, 15, 30, 60 and 120 min fibrinogen and high molecular weight kininogen (HMWK) adsorption was measured by a newly developed modified ELISA technique. In addition, changes in coagulation and platelet activation were measured by well established assays. High concentrations of fibrinogen were detected after very short blood material contact, both on uncoated as well as heparin-coated tubes. However, high amounts of HMWK were only found on the heparin-bonded surfaces. In addition, the concentrations of the soluble coagulation marker prothrombin fragment F1+2 and the marker for platelet activation beta-thromboglobulin were significantly higher in the non-coated tubes. We presume that adsorption of HMWK to heparin-coated surfaces contributes to the improved hemocompatibility of these bondings.

Adsorption↗
PubMed1999

Transmyocardial laser revascularization in the acute ischaemic heart: no improvement of acute myocardial perfusion or prevention of myocardial infarction.

OBJECTIVE: Transmyocardial laser revascularization (TMLR) has been used to provide enhanced myocardial perfusion in patients not suitable for coronary revascularization or angioplasty. This study investigates the acute changes in myocardial perfusion after TMLR with a Holmium:Yttrium-Aluminium-Garnet (YAG) laser with a thermal imaging camera in a model of acute ischaemia, and confirms its midterm effects by post-mortem investigation of magnetic resonance imaging and histopathological examination. METHODS: Acute myocardial ischaemia was induced by occlusion of the dominant diagonal branch in ten sheep. Perfusion measurements were undertaken first in the unaffected myocardium, then after temporary occlusion of the coronary to obtain a control measurement for ischaemic myocardium. Myocardial perfusion was then evaluated during reperfusion after release of coronary occlusion. Then the coronary was permanently occluded and 20.5+/-2 channels were drilled with the Holmium:YAG laser and perfusion was measured again. The other four sheep served as control with untreated ischaemia. All animals were sacrificed after 28 days following administration of gadolinium i.v. to serve as contrast medium for magnetic resonance tomography. The hearts were subjected to magnetic resonance tomography and histopathological examination. RESULTS: Intraoperative perfusion measurements revealed a decreased perfusion after temporary occlusion and an increased perfusion in reperfused myocardium. After TMLR, no improvement of myocardial perfusion above the ischaemic level could be shown. Magnetic resonance images could neither confirm patent laser channels nor viable myocardium within ischaemic areas. On histology no patent endocardial laser channel could be detected. The transmural features were myocardial infarct with scar tissue. CONCLUSIONS: In the presented sheep model with acute ischaemia, TMLR with a Holmium:YAG laser did not provide acute improvement of myocardial perfusion as assessed by a thermal imaging camera. This would suggest no direct contribution of newly created laser channels to myocardial perfusion. As chronic effects are concerned, no perfused laser channels could be identified by later magnetic resonance imaging or histology.

Animals↗
PubMed1999

Coating-techniques to improve the hemocompatibility of artificial devices used for extracorporeal circulation.

OBJECTIVE: Extracorporeal circulation procedures have been shown to induce complement and leukocyte activation, release of endotoxin and inflammatory mediators, including cytokines, nitric oxide, oxygen free radicals, and platelet activating factors. The contact between the blood and the various artificial surfaces of the extracorporeal system results in an unspecific post-perfusion syndrome. For diminishing these negative side effects several coating-techniques have been developed to create devices with improved hemocompatibility. METHODS: This review deals with the current knowledge of heparin-coated and otherwise surface-modified perfusion systems. The pathway how heparin-coated surfaces work is discussed and techniques for surface-coatings, both clinically introduced as well as newly developed are presented. RESULTS: Numerous clinical studies compared heparin-coated versus non-coated circuits. Heparin-bonded devices showed lessened humoral and cellular activation, in particular a reduced complement activation with a reduced inflammatory post-perfusion syndrome. Also platelet protection and more favorable post-operative lung function are of particular note. Recent clinical trials demonstrated shortened hospital stays, less drainage bleeding, and reduced cerebral complications using heparin-coated oxygenation systems. The diminished expression of the leukocyte adhesion molecules CD 11b/c in CBAS devices points to a decreased activation of neutrophils. In addition, one research group found a reduced production of oxygen radicals. Heparin-bonding minimizes oxygenator failure by a significant reduced pressure gradient across the oxygenator, probably caused by decreased fibrin and platelet deposition at the hollow fiber surfaces. A meta analysis examined the impact of heparin-bonded systems on clinical outcomes and resulting costs. Using heparin-bonded circuits led to total cost savings from US $1000 to 3000. Several authors demonstrated reduced blood loss and better clinical outcome by reduction of systemic heparinization and the employment of heparin-coated devices. CONCLUSION: Above and beyond the long-term applications, routine heart operations have also markedly begun to utilize heparin-coated devices. This trend will assuredly continue in the coming years and is an important step toward higher hemocompatibility of blood-contacting surfaces in the ECC device. Heparin-coatings are merely the beginning of improved hemocompatibility for all materials that come into contact with human blood or tissues. Intelligent materials with almost completely physiological surfaces will be at the surgeon's disposal within the next few years.

Animals↗
PubMed1999

Improvement of non-small-cell lung cancer staging by means of positron emission tomography.

BACKGROUND: Exact staging of ipsi- and contralateral mediastinal lymph-node metastases (N 1/2 vs. N3) is essential for the therapeutic strategy in non-small-cell lung cancer (NSCLC). CT and mediastinoscopy are the standards of reference for N staging. However, even with these combined measures the extent of invasion of mediastinal lymph nodes can remain vague. 18FDG Positron Emission Tomography (18FDG-PET) has recently been shown to detect invaded nodes with high accuracy. The purpose of this study was to evaluate 18FDG-PET as an aid in N staging. METHODS: 27 patients with suspected NSCLC were clinically staged by means of CT, bronchoscopy, mediastinoscopy, and bone scintigraphy. Additionally, 18FDG-PET was performed preoperatively for analysis of topography of invaded lymph nodes. CT and 18FDG-PET were evaluated in a blinded fashion. Surgical therapy was performed with radical lymphadenectomy. CT N staging as well as PET N staging results were compared with the pathological diagnoses (pTN). Specificity, sensitivity, and accuracy of CT and PET in N staging were calculated. RESULTS: 14 squamous-cell carcinomas, 10 adenocarcinomas, and 3 non-malignant tumors were found. In 8 patients no invasion was found (N0), in 13 patients an ipsilateral invasion (N1/2), and in 3 patients a contralateral invasion (N3). In the correct detection of N1/2 the sensitivity of CT and of PET was 0.77, the specificity of CT and of PET was 0.79. The accuracy of CT was 0.74 and of PET 0.78. By combining CT and PET accuracy was 0.85. CONCLUSIONS: Adequate preoperative LN staging is possible with both CT and 18FDG-PET. The accuracy, however, can be improved by a combination of CT and 18FDG-PET.

Adenocarcinoma↗
PubMed1999

Transmyocardial laser revascularization with the Holmium:YAG laser does not improve myocardial perfusion in the acutely ischemic heart: an experimental study measuring myocardial perfusion by a thermal imaging camera.

BACKGROUND: Transmyocardial laser revascularization (TMLR) is a new surgical therapy for patients with end-stage coronary artery disease refractory to conventional therapy. TMLR should act by improvement of perfusion of the lasered myocardium. Blood should be delivered from the cavity of the heart to the surface of the myocardium. The aim of this study was to measure perfusion of normal, ischemic, and ischemic myocardium after TMLR. METHOD: We used a new method of perfusion measurement by an infrared thermal imaging system in an open-chested adult sheep model with temporary and permanent occlusion of the dominant diagonal branch. RESULTS: A significant fall from normal perfusion of the myocardium to reduced after inducing ischemia (p<0.01) and a significant rise again after reperfusion (p<0.001) could be shown. Perfusion measurements after TMLR did not significantly differ from perfusion measurements after inducing ischemia (p=0.2). CONCLUSION: In the presented sheep model, laser revascularization could not improve myocardial perfusion after acute ischemia as seen by the infrared thermal imaging system.

Aluminum↗
PubMed1999

Haemocompatibility of paediatric membrane oxygenators with heparin-coated surfaces.

Extracorporeal circulation (ECC) in paediatric patients with heparin-coated oxygenation systems is rarely investigated. The objective of this study was to evaluate, preclinically, the haemocompatibility of paediatric membrane oxygenators with heparin-coated surfaces. We compared 16 paediatric membrane oxygenators (Minimax, Medtronic) in an in vitro heart-lung machine model with fresh human blood. Eight of these oxygenation systems had a covalent heparin coating (Carmeda bioactive surface). After 90 min simulated ECC, the heparin-coated systems showed significantly higher platelet count, lower platelet-factor 4 release, reduced contact activation (factor XIIa and kallikrein), and lower neutrophil elastase levels (p < 0.05), compared to the noncoated oxygenator group. More biocompatible materials for paediatric operations may ameliorate the various postperfusion syndromes arising from ECC procedures, particularly unspecific inflammation, hyperfibrinolysis and blood loss.

Biocompatible Materials↗
PubMed1998

Left ventricular geometry and cardiac function during minimally invasive coronary artery bypass grafting.

BACKGROUND: This investigation was designed to study the changes in function and geometry of the left ventricle during two critical steps of minimally invasive direct coronary artery bypass procedures: placement of an epicardial stabilizer and occlusion of the left anterior descending coronary artery. METHODS: Between February 1997 and January 1998, 28 patients underwent bypass grafting with the left internal thoracic artery to the left anterior descending coronary artery (minimally invasive direct coronary artery bypass technique). Transesophageal echocardiography was used for determination of fractional area change and to assess left ventricular (LV) diameters in two dimensions and at the apex. RESULTS: Placement of the epicardial stabilizer resulted in a small decrease in LV end-systolic and end-diastolic dimensions; cardiac function remained unchanged. Subsequent occlusion of the left anterior descending coronary artery caused a moderate decline in cardiac index and fractional area change, an increase in LV diameters, and the development of hypokinetic segments within the LV myocardium. CONCLUSIONS: The use of an epicardial stabilizer provides a safe and effective means to stabilize the operative field during minimally invasive direct coronary artery bypass procedures. Monitoring of LV function by transesophageal echocardiography enhances the safety of such procedures and is highly recommended.

Aged↗
PubMed1998

Fibrin sealant, aprotinin, and immune response in children undergoing operations for congenital heart disease.

OBJECTIVE: Most commercially available fibrin sealants contain aprotinin in doses of 1500 kallikrein inactivator units per milliliter. They are used in many operative disciplines. An elevated risk of hypersensitivity reactions exists at reexposure to aprotinin. Our aim was to examine the immunogenic potency of aprotinin as a fibrin sealant content. METHODS: We investigated 49 children with operatively treated congenital heart disease. All patients received aprotinin only topically as contained in fibrin sealant. Serum samples were drawn preoperatively, 1 week, 2 weeks, 6 weeks, and approximately 1 year after operation. They were analyzed for aprotinin-specific immunoglobulin G antibodies with a standard enzyme-linked immunosorbent assay and a fluorescence enzyme immunoassay for aprotinin-specific immunoglobulin E antibodies. RESULTS: At 1 week, 2 weeks, 6 weeks, and 1 year, we found prevalences of 8% (2 of 26), 8% (2 of 24), 6% (3 of 49), and 0% for aprotinin-specific Immunoglobulin E, and for aprotinin-specific immunoglobulin G 8% (2 of 26), 17% (4 of 24), 39% (19 of 49), and 12% (5 of 41). The doses of aprotinin given did not differ significantly in antibody-negative and antibody-positive patients; no significant factors could predict the immune response. CONCLUSIONS: Our findings show the existence of a subgroup of patients who had aprotinin-specific antibodies develop after topical aprotinin application. Any use of aprotinin must be carefully documented. If aprotinin use is planned in patients who previously underwent a surgical procedure, preexposure to aprotinin in any form must be sought to avoid unexpected anaphylactic reactions. The necessity itself and alternatives for aprotinin as a stabilizing agent in fibrin sealants merit consideration.

Anaphylaxis↗
PubMed1998

Combined Norwood and Rastelli procedure for repair of interrupted aortic arch with subaortic stenosis.

A neonate presented with an interrupted aortic arch type B and VSD with dysplastic aortic valve, subaortic stenosis, and aberrant right subclavian artery. We performed a direct anastomosis between the hypoplastic ascending aorta (0 3 mm), the main pulmonary artery and the descending aorta, mimicking a Norwood-type ventricular outlet. The right-ventricular outflow tract was reconstructed with a 8mm PTFE vascular graft. This combination of a modified Norwood with a Rastelli procedure facilitated establishment of a sufficiently large left-ventricular outflow tract via VSD, at the same time maintaining a biventricular system despite the coexisting anomalies.

Abnormalities, Multiple↗
PubMed1998

Effect of a single element subcutaneous array electrode added to a transvenous electrode configuration on the defibrillation field and the defibrillation threshold.

Even with the use of biphasic shocks, up to 5% of patients need an additional subcutaneous lead to obtain a defibrillation safety margin of at least 10 J. The number of patients requiring additional subcutaneous leads may even increase, because recent generation devices have a < 34 J maximum output in order to decrease their size. In 20 consecutive patients, a single element subcutaneous array lead was implanted in addition to a transvenous lead system consisting of a right ventricular (RV) and a vena cava superior lead using a single infraclavicular incision. The RV lead acted as the cathode; the subcutaneous lead and the lead in the subclavian vein acted as the anode. The biphasic defibrillation threshold was determined using a binary search protocol. Patients were randomized as to whether to start them with the transvenous lead configuration or the combination of the transvenous lead and the subcutaneous lead. In addition, a simplified assessment of the defibrillation field was performed by determining the interelectrode area for the transvenous lead only and the transvenous lead in combination with the subcutaneous lead from a biplane chest X ray. The intraoperative defibrillation threshold was reconfirmed after 1 week, after 3 months, and after 12 months. The mean defibrillation threshold with the additional subcutaneous lead was significantly (P = 0.0001) lower (5.7 +/- 2.9 J) than for the transvenous lead system (9.5 +/- 4.6 J). With the subcutaneous lead, the impedance of the high voltage circuit decreased from 48.9 +/- 7.4 omega to 39.2 +/- 5.0 omega. In the frontal plane, the interelectrode area increased by 11.3% +/- 5.5% (P < 0.0001) and in the lateral plane by 29.5% +/- 12.4% (P < 0.0001). The defibrillation threshold did not increase during follow-up. Complications with the subcutaneous electrode were not observed during a follow-up of 15.8 +/- 2 months. The single finger array lead is useful in order to lower the defibrillation threshold and can be used in order to lower the defibrillation threshold.

Aged↗